$ASTH
Astrana Health, Inc.

2019 Form 10-K Financial Statement

#000162828020003626 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018
Revenue $560.6M $105.5M $519.9M
YoY Change 7.83% -59.34% 45.9%
Cost Of Revenue $467.8M $79.40M $361.1M
YoY Change 29.54% -55.99% 32.06%
Gross Profit $92.81M $26.00M $158.8M
YoY Change -41.54% -67.13% 91.52%
Gross Profit Margin 16.56% 24.64% 30.54%
Selling, General & Admin $40.10M $15.80M $47.20M
YoY Change -15.04% 54.9% 80.15%
% of Gross Profit 43.21% 60.77% 29.73%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $18.28M $4.480M $19.30M
YoY Change -5.3% -76.13% 1.19%
% of Gross Profit 19.7% 17.23% 12.16%
Operating Expenses $528.2M $20.30M $431.5M
YoY Change 22.42% -33.66% 34.33%
Operating Profit $32.42M $5.700M $88.43M
YoY Change -63.34% -88.25% 151.61%
Interest Expense $4.733M -$5.400M $561.0K
YoY Change 743.67% -138.85% 603.99%
% of Operating Profit 14.6% -94.74% 0.63%
Other Income/Expense, Net -$6.580M $500.0K -$5.805M
YoY Change 13.35% 400.0% -139.86%
Pretax Income $25.84M -$2.900M $82.63M
YoY Change -68.73% -104.63% 66.21%
Income Tax $8.167M -$1.000M $22.36M
% Of Pretax Income 31.61% 27.06%
Net Earnings $14.12M -$3.100M $10.84M
YoY Change 30.28% -108.18% -58.01%
Net Earnings / Revenue 2.52% -2.94% 2.08%
Basic Earnings Per Share $0.41 $0.33
Diluted Earnings Per Share $0.39 -$92.26K $0.29
COMMON SHARES
Basic Shares Outstanding 34.71M shares 34.08M shares 32.89M shares
Diluted Shares Outstanding 36.40M shares 37.91M shares

Balance Sheet

Concept 2019 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $219.7M $108.0M $108.0M
YoY Change 103.43% 7.04% 7.04%
Cash & Equivalents $103.2M $106.9M $106.9M
Short-Term Investments $116.5M $1.100M $1.100M
Other Short-Term Assets $10.40M $8.400M $8.400M
YoY Change 23.81% -60.19% -60.19%
Inventory
Prepaid Expenses
Receivables $59.10M $7.735M $56.50M
Other Receivables $39.90M $1.003M $0.00
Total Short-Term Assets $329.1M $172.9M $172.9M
YoY Change 90.34% 19.91% 19.9%
LONG-TERM ASSETS
Property, Plant & Equipment $26.40M $12.72M $12.70M
YoY Change 107.87% -7.91% -7.97%
Goodwill $185.8M
YoY Change 115.56%
Intangibles $86.88M
YoY Change -16.09%
Long-Term Investments $29.30M $34.88M $35.30M
YoY Change -17.0% 59.23% 61.19%
Other Assets $2.400M $1.206M $2.000M
YoY Change 20.0% -26.12% -16.67%
Total Long-Term Assets $399.6M $340.1M $340.1M
YoY Change 17.49% -1.83% -1.82%
TOTAL ASSETS
Total Short-Term Assets $329.1M $172.9M $172.9M
Total Long-Term Assets $399.6M $340.1M $340.1M
Total Assets $728.7M $513.0M $513.0M
YoY Change 42.05% 4.56% 4.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.60M $4.482M $8.600M
YoY Change 58.14% 18.36% 330.0%
Accrued Expenses $6.200M $5.000M $5.000M
YoY Change 24.0% -76.74% -76.74%
Deferred Revenue $9.024M
YoY Change 3509.69%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $9.600M $0.00 $100.0K
YoY Change 9500.0% -100.0% 0.0%
Total Short-Term Liabilities $105.4M $72.02M $72.00M
YoY Change 46.39% -34.29% -34.31%
LONG-TERM LIABILITIES
Long-Term Debt $232.6M $0.00 $13.50M
YoY Change 1622.96% -100.0% 2150.0%
Other Long-Term Liabilities $11.40M $1.200M $1.200M
YoY Change 850.0% -93.75% -93.75%
Total Long-Term Liabilities $244.0M $34.32M $14.70M
YoY Change 1559.86% -23.26% -25.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $105.4M $72.02M $72.00M
Total Long-Term Liabilities $244.0M $34.32M $14.70M
Total Liabilities $537.2M $106.3M $332.5M
YoY Change 61.56% -31.09% 0.54%
SHAREHOLDERS EQUITY
Retained Earnings $17.79M
YoY Change 925.53%
Common Stock $34.58K
YoY Change 7.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $191.5M $180.5M $180.5M
YoY Change
Total Liabilities & Shareholders Equity $728.7M $513.0M $513.0M
YoY Change 42.05% 4.56% 4.57%

Cashflow Statement

Concept 2019 2018 Q4 2018
OPERATING ACTIVITIES
Net Income $14.12M -$3.100M $10.84M
YoY Change 30.28% -108.18% -58.01%
Depreciation, Depletion And Amortization $18.28M $4.480M $19.30M
YoY Change -5.3% -76.13% 1.19%
Cash From Operating Activities $13.67M -$6.360M $25.50M
YoY Change -46.37% -120.93% -50.81%
INVESTING ACTIVITIES
Capital Expenditures $1.042M -$300.0K $1.170M
YoY Change -10.94% -85.15% -43.88%
Acquisitions $49.40M $0.00
YoY Change
Other Investing Activities -$179.6M -$4.630M -$24.01M
YoY Change 647.98% -146.02% -183.37%
Cash From Investing Activities -$180.6M -$4.930M -$25.18M
YoY Change 617.27% -161.39% -194.26%
FINANCING ACTIVITIES
Cash Dividend Paid $61.72M $17.76M
YoY Change 247.53% 69.97%
Common Stock Issuance & Retirement, Net $7.570M $4.847M
YoY Change 56.18% 377.49%
Debt Paid & Issued, Net $2.375M $0.00
YoY Change
Cash From Financing Activities $163.3M -5.810M -$11.18M
YoY Change -1561.44% -61.34% -25.37%
NET CHANGE
Cash From Operating Activities $13.67M -6.360M $25.50M
Cash From Investing Activities -$180.6M -4.930M -$25.18M
Cash From Financing Activities $163.3M -5.810M -$11.18M
Net Change In Cash -$3.627M -17.10M -$10.86M
YoY Change -66.61% -173.14% -117.09%
FREE CASH FLOW
Cash From Operating Activities $13.67M -$6.360M $25.50M
Capital Expenditures $1.042M -$300.0K $1.170M
Free Cash Flow $12.63M -$6.060M $24.33M
YoY Change -48.08% -118.7% -51.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 ameh Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
-781924 USD
CY2019 ameh Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
135155 USD
CY2018 ameh Adjustments To Additional Paid In Capital Merger Purchase Price Adjustment
AdjustmentsToAdditionalPaidInCapitalMergerPurchasePriceAdjustment
868000 USD
CY2019Q3 ameh All Inclusive Population Based Payments To Be Received
AllInclusivePopulationBasedPaymentsToBeReceived
3700000 USD
CY2017 ameh Antidilutive Securities Excluded From Earnings Computation Shares
AntidilutiveSecuritiesExcludedFromEarningsComputationShares
1682110 shares
CY2018 ameh Antidilutive Securities Excluded From Earnings Computation Shares
AntidilutiveSecuritiesExcludedFromEarningsComputationShares
1682110 shares
CY2019 ameh Antidilutive Securities Excluded From Earnings Computation Shares
AntidilutiveSecuritiesExcludedFromEarningsComputationShares
17290317 shares
CY2017Q4 ameh Billing In Excess Of Costs
BillingInExcessOfCosts
34500000 USD
CY2018Q4 ameh Billing In Excess Of Costs
BillingInExcessOfCosts
7800000 USD
CY2018 ameh Business Acquisition Pro Forma Net Income Loss Including Portion Attributable To Noncontrolling Interest
BusinessAcquisitionProFormaNetIncomeLossIncludingPortionAttributableToNoncontrollingInterest
58879491 USD
CY2019 ameh Business Acquisition Pro Forma Net Income Loss Including Portion Attributable To Noncontrolling Interest
BusinessAcquisitionProFormaNetIncomeLossIncludingPortionAttributableToNoncontrollingInterest
10867496 USD
CY2017 ameh Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic
25525786 shares
CY2017 ameh Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted
28661735 shares
CY2017Q4 ameh Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash
745220 USD
CY2017Q4 ameh Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Medical Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities
39353540 USD
CY2017Q4 ameh Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable
5376215 USD
CY2017Q4 ameh Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable To Related Party
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty
9921938 USD
CY2017Q4 ameh Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Line Of Credit
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit
25000 USD
CY2017Q4 ameh Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
0.1
CY2017 ameh Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
0.1
CY2018 ameh Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
0.1
CY2019 ameh Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
0.1
CY2017Q4 ameh Business Combination Shares Held Back To Secure Indemnification Period
BusinessCombinationSharesHeldBackToSecureIndemnificationPeriod
P024M
CY2017Q4 ameh Business Combination Shares Held Back To Secure Indemnification Shares Issued On First Anniversary Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationSharesIssuedOnFirstAnniversaryPercentage
0.5
CY2017Q4 ameh Business Combination Shares Held Back To Secure Indemnification Shares Issued On Second Anniversary Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationSharesIssuedOnSecondAnniversaryPercentage
0.5
CY2017 ameh Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0 USD
CY2018 ameh Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
109 USD
CY2019 ameh Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0 USD
CY2018 ameh Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
30189 shares
CY2019 ameh Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
0 shares
CY2017 ameh Class Of Warrant Or Rights Assumed From Merger Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsAssumedFromMergerWeightedAverageRemainingContractualTerm
P2Y8M9D
CY2017 ameh Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P5Y0M0D
CY2016 ameh Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
P0Y
CY2017 ameh Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
P3Y8M26D
CY2018 ameh Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
P2Y11M19D
CY2019 ameh Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
P2Y4D
CY2017Q4 ameh Class Of Warrants Or Right Assumed Rom Merger Aggregate Intrinsic Value
ClassOfWarrantsOrRightAssumedRomMergerAggregateIntrinsicValue
1800000 USD
CY2017 ameh Class Of Warrants Or Right Exercise Price Of Warrants Assumed From Merger
ClassOfWarrantsOrRightExercisePriceOfWarrantsAssumedFromMerger
9.06
CY2018Q4 ameh Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
3000000 USD
CY2019Q4 ameh Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
1600000 USD
CY2016Q4 ameh Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
0 USD
CY2017Q4 ameh Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
52000000 USD
CY2018Q4 ameh Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
33100000 USD
CY2019Q4 ameh Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
26700000 USD
CY2016Q4 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
0.00
CY2017Q4 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
9.75
CY2018Q4 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
9.93
CY2019Q4 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
9.96
CY2018 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Exercised In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
7.84
CY2019 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Exercised In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
9.32
CY2018 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Forfeited In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
4.50
CY2019 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Forfeited In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
0.00
CY2017 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
10.49
CY2018 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
0.00
CY2019 ameh Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
0.00
CY2018Q4 ameh Deferred Tax Assets Investment
DeferredTaxAssetsInvestment
884922 USD
CY2019Q4 ameh Deferred Tax Assets Investment
DeferredTaxAssetsInvestment
2977431 USD
CY2019Q4 ameh Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
3567302 USD
CY2018Q4 ameh Deferred Tax Liabilities Risk Pool Receivable
DeferredTaxLiabilitiesRiskPoolReceivable
2434573 USD
CY2019Q4 ameh Deferred Tax Liabilities Risk Pool Receivable
DeferredTaxLiabilitiesRiskPoolReceivable
1623049 USD
CY2017 ameh Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
0 USD
CY2018 ameh Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
1110456 USD
CY2019 ameh Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
6334368 USD
CY2019 ameh Defined Contribution Plan Service Period
DefinedContributionPlanServicePeriod
P6M
CY2019 ameh Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P6Y
CY2017 ameh Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
19075353 USD
CY2019 ameh Gain Loss On Assumption Of Loan
GainLossOnAssumptionOfLoan
2250000 USD
CY2018 ameh Goodwill Decrease Merger Transaction Costs
GoodwillDecreaseMergerTransactionCosts
900000 USD
CY2017 ameh Increase Decrease In Capitation Incentives Payable
IncreaseDecreaseInCapitationIncentivesPayable
1878355 USD
CY2017 ameh Gain Loss On Assumption Of Loan
GainLossOnAssumptionOfLoan
0 USD
CY2018 ameh Gain Loss On Assumption Of Loan
GainLossOnAssumptionOfLoan
0 USD
CY2018 ameh Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
19303179 USD
CY2019 ameh Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
18280198 USD
CY2017 ameh Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Entity Conversion Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsEntityConversionPercent
0.000
CY2018 ameh Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Entity Conversion Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsEntityConversionPercent
0.005
CY2019 ameh Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Entity Conversion Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsEntityConversionPercent
-0.105
CY2017 ameh Effective Income Tax Rate Reconciliation Federal Rate Adjustment
EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
-0.097
CY2018 ameh Effective Income Tax Rate Reconciliation Federal Rate Adjustment
EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
0.013
CY2019 ameh Effective Income Tax Rate Reconciliation Federal Rate Adjustment
EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
0.033
CY2018Q4 ameh Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
1538598 USD
CY2019Q4 ameh Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
2027081 USD
CY2018 ameh Increase Decrease In Capitation Incentives Payable
IncreaseDecreaseInCapitationIncentivesPayable
-21500000 USD
CY2019 ameh Increase Decrease In Capitation Incentives Payable
IncreaseDecreaseInCapitationIncentivesPayable
0 USD
ameh Increase Decrease In Deferred Tax Assets Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate
-6600000 USD
ameh Increase Decrease In Deferred Tax Liabilities Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate
-16300000 USD
CY2017 ameh Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
5661313 USD
CY2018 ameh Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
4134209 USD
CY2019 ameh Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
-2391459 USD
CY2019 ameh Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
2479862 USD
CY2019 ameh Increase Decrease In Other Operating Lease Liabilities
IncreaseDecreaseInOtherOperatingLeaseLiabilities
-2243511 USD
CY2017 ameh Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-1260064 USD
CY2018 ameh Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
2813564 USD
CY2019 ameh Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
2755599 USD
CY2018Q4 ameh Investment In Privately Held Entity That Does Not Report Net Asset Value
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
405000 USD
CY2019Q4 ameh Investment In Privately Held Entity That Does Not Report Net Asset Value
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
896000 USD
CY2018Q4 ameh Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
1185025 USD
CY2019Q4 ameh Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
0 USD
CY2018 ameh Malpractice Loss Contingency Claims Incurredin Acquired Liabilities
MalpracticeLossContingencyClaimsIncurredinAcquiredLiabilities
0 USD
CY2019 ameh Malpractice Loss Contingency Claims Incurredin Acquired Liabilities
MalpracticeLossContingencyClaimsIncurredinAcquiredLiabilities
25236286 USD
CY2018 ameh Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
0 USD
CY2019 ameh Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
27474440 USD
CY2017Q4 ameh Medical Liabilities Current
MedicalLiabilitiesCurrent
63972318 USD
CY2018Q4 ameh Medical Liabilities Current
MedicalLiabilitiesCurrent
33641701 USD
CY2019Q4 ameh Medical Liabilities Current
MedicalLiabilitiesCurrent
58724682 USD
CY2017 ameh Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
27352116 USD
CY2018 ameh Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
12377614 USD
CY2019 ameh Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
15865570 USD
CY2019 ameh Non Cash Reclassification Of Deferred Tax Liabilities
NonCashReclassificationOfDeferredTaxLiabilities
900000 USD
CY2017 ameh Noncashor Part Noncash Acquisition Conversionof Loan Receivableto Investment Interest
NoncashorPartNoncashAcquisitionConversionofLoanReceivabletoInvestmentInterest
0 USD
CY2018 ameh Noncashor Part Noncash Acquisition Conversionof Loan Receivableto Investment Interest
NoncashorPartNoncashAcquisitionConversionofLoanReceivabletoInvestmentInterest
5000000 USD
CY2019 ameh Noncashor Part Noncash Acquisition Conversionof Loan Receivableto Investment Interest
NoncashorPartNoncashAcquisitionConversionofLoanReceivabletoInvestmentInterest
0 USD
CY2017 ameh Noncontrolling Interest Increase From Capital Charge
NoncontrollingInterestIncreaseFromCapitalCharge
859430 USD
CY2018 ameh Noncontrolling Interest Increase From Capital Charge
NoncontrollingInterestIncreaseFromCapitalCharge
27500 USD
CY2019 ameh Noncontrolling Interest Increase From Capital Charge
NoncontrollingInterestIncreaseFromCapitalCharge
27500 USD
CY2017Q4 ameh Number Of Shares Holdback Percentage
NumberOfSharesHoldbackPercentage
0.10
CY2017 ameh Number Of Warrants Assumed From Merger
NumberOfWarrantsAssumedFromMerger
1898541 shares
CY2018 ameh Number Of Warrants Exercised
NumberOfWarrantsExercised
286357 shares
CY2019 ameh Number Of Warrants Exercised
NumberOfWarrantsExercised
177405 shares
CY2017 ameh Number Of Warrants Granted
NumberOfWarrantsGranted
1750000 shares
CY2018 ameh Number Of Warrants Granted
NumberOfWarrantsGranted
0 shares
CY2019 ameh Number Of Warrants Granted
NumberOfWarrantsGranted
0 shares
CY2018 ameh Operating Loss Carryforwards Limitation Rate On Taxable Income
OperatingLossCarryforwardsLimitationRateOnTaxableIncome
0.8
CY2017 ameh Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share
PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
0 USD
CY2018 ameh Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share
PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
405000 USD
CY2019 ameh Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share
PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
491000 USD
CY2018Q1 ameh Payment Of Revenue
PaymentOfRevenue
7300000 USD
ameh Payment Of Revenue
PaymentOfRevenue
8300000 USD
CY2018Q4 ameh Payment Of Revenue Reduce
PaymentOfRevenueReduce
5500000 USD
CY2018 ameh Payments To Cms Based For Medical Liabilities
PaymentsToCMSBasedForMedicalLiabilities
34464826 USD
CY2019 ameh Payments To Cms Based For Medical Liabilities
PaymentsToCMSBasedForMedicalLiabilities
0 USD
CY2019 ameh Percentage Of Financial Guarantee Benchmark Amount
PercentageOfFinancialGuaranteeBenchmarkAmount
0.02
CY2017 ameh Proceeds From Stock Options Exercised Included In Liabilities
ProceedsFromStockOptionsExercisedIncludedInLiabilities
425025 USD
CY2018 ameh Proceeds From Stock Options Exercised Included In Liabilities
ProceedsFromStockOptionsExercisedIncludedInLiabilities
0 USD
CY2019 ameh Proceeds From Stock Options Exercised Included In Liabilities
ProceedsFromStockOptionsExercisedIncludedInLiabilities
0 USD
CY2017 ameh Proceeds On Sale Of Investment Privately Held Entity That Does Not Report Nav Pershare
ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare
25000 USD
CY2018 ameh Proceeds On Sale Of Investment Privately Held Entity That Does Not Report Nav Pershare
ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare
0 USD
CY2019 ameh Proceeds On Sale Of Investment Privately Held Entity That Does Not Report Nav Pershare
ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare
0 USD
CY2019Q4 ameh Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
16023176 USD
CY2019Q4 ameh Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12129901 USD
CY2019Q4 ameh Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
28153077 USD
CY2017 ameh Purchase Price Adjustmentfor Accelerationof Vested Stock Options
PurchasePriceAdjustmentforAccelerationofVestedStockOptions
0 USD
CY2018 ameh Purchase Price Adjustmentfor Accelerationof Vested Stock Options
PurchasePriceAdjustmentforAccelerationofVestedStockOptions
900000 USD
CY2018 ameh Purchase Price Adjustmentfor Accelerationof Vested Stock Options
PurchasePriceAdjustmentforAccelerationofVestedStockOptions
868000 USD
CY2019 ameh Purchase Price Adjustmentfor Accelerationof Vested Stock Options
PurchasePriceAdjustmentforAccelerationofVestedStockOptions
0 USD
CY2017 ameh Reclassification Of Aps Non Controlling Interest To Equity
ReclassificationOfAPSNonControllingInterestToEquity
0 USD
CY2018 ameh Reclassification Of Aps Non Controlling Interest To Equity
ReclassificationOfAPSNonControllingInterestToEquity
2832180 USD
CY2019 ameh Reclassification Of Aps Non Controlling Interest To Equity
ReclassificationOfAPSNonControllingInterestToEquity
0 USD
CY2017 ameh Reclassification Of Dividends Related To Shares Repurchase
ReclassificationOfDividendsRelatedToSharesRepurchase
0 USD
CY2018 ameh Reclassification Of Dividends Related To Shares Repurchase
ReclassificationOfDividendsRelatedToSharesRepurchase
4216202 USD
CY2019 ameh Reclassification Of Dividends Related To Shares Repurchase
ReclassificationOfDividendsRelatedToSharesRepurchase
0 USD
CY2017 ameh Reclassification Of Liability For Equity
ReclassificationOfLiabilityForEquity
0 USD
CY2018 ameh Reclassification Of Liability For Equity
ReclassificationOfLiabilityForEquity
0 USD
CY2019 ameh Reclassification Of Liability For Equity
ReclassificationOfLiabilityForEquity
1185025 USD
CY2017 ameh Reclassification Of Liability For Unissued Common Shares Payable To Equity
ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity
1237650 USD
CY2018 ameh Reclassification Of Liability For Unissued Common Shares Payable To Equity
ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity
0 USD
CY2019 ameh Reclassification Of Liability For Unissued Common Shares Payable To Equity
ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity
0 USD
CY2017 ameh Repayments Of Bank Loan And Lines Of Credit
RepaymentsOfBankLoanAndLinesOfCredit
0 USD
CY2018 ameh Repayments Of Bank Loan And Lines Of Credit
RepaymentsOfBankLoanAndLinesOfCredit
495134 USD
CY2019 ameh Repayments Of Bank Loan And Lines Of Credit
RepaymentsOfBankLoanAndLinesOfCredit
52640258 USD
CY2017 ameh Risk Pool Settlement
RiskPoolSettlement
5900000 USD
CY2017 ameh Stock Issued During Period Value Merger
StockIssuedDuringPeriodValueMerger
64421383 USD
CY2018 ameh Risk Pool Settlement
RiskPoolSettlement
900000 USD
CY2018 ameh Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
151346 shares
CY2019 ameh Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
0 shares
CY2018 ameh Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period Net
ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriodNet
109438 shares
CY2018 ameh Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
286357 shares
CY2019 ameh Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
177405 shares
CY2018Q4 ameh Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
300000 USD
CY2019Q4 ameh Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
2812652 USD
CY2017Q4 ameh Stock Issued During Period Share Conversion Of Notes
StockIssuedDuringPeriodShareConversionOfNotes
520081 shares
CY2019 ameh Stock Issued During Period Shares Merger
StockIssuedDuringPeriodSharesMerger
535392 shares
CY2017 ameh Stock Issued During Period Value Conversion Of Liability To Equity
StockIssuedDuringPeriodValueConversionOfLiabilityToEquity
1237650 USD
CY2017Q4 ameh Stock Issued During Period Value Conversion Of Notes
StockIssuedDuringPeriodValueConversionOfNotes
5400000 USD
CY2018 ameh Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
3996680 USD
CY2019 ameh Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
3233242 USD
CY2018Q4 ameh Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
2532750 USD
CY2019Q4 ameh Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
3360282 USD
CY2018 ameh Warrant Issued During Period Value Stock Options Exercised
WarrantIssuedDuringPeriodValueStockOptionsExercised
2200000 USD
CY2019 ameh Warrant Issued During Period Value Stock Options Exercised
WarrantIssuedDuringPeriodValueStockOptionsExercised
1700000 USD
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001083446
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52804187 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q2 dei Entity Public Float
EntityPublicFloat
480100000 USD
CY2019 dei Entity Registrant Name
EntityRegistrantName
Apollo Medical Holdings, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25075489 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
27279579 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4481544 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6914680 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7734631 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11003563 USD
CY2018Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
48721325 USD
CY2019Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
48136313 USD
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11621861 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4528867 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2251741 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1837434 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14000966 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162723051 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
159608293 USD
CY2017 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
5294000 USD
CY2018 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2019 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2113116 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
809528 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
607146 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4300000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2900000 USD
CY2019 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.21
CY2017 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.35
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.25
CY2019 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.20
CY2017 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.39
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.29
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17500000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17100000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16300000 USD
CY2018Q4 us-gaap Assets
Assets
512999049 USD
CY2019Q4 us-gaap Assets
Assets
728713347 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
172862792 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
329068418 USD
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
86627847 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
167269681 USD
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
340136257 USD
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
399644929 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1066103 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
116468555 USD
CY2017Q4 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
6109205 shares
CY2017 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
6109205 shares
CY2017Q4 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
0.18
CY2017Q4 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
10.00
CY2017 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
9982706 USD
CY2018 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
9447002 USD
CY2019 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
7310724 USD
CY2017 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
478873780 USD
CY2018 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
726074752 USD
CY2019 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
658010954 USD
CY2017Q4 us-gaap Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
3142000 USD
CY2017Q4 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
86394383 USD
CY2017Q4 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
61092050 USD
CY2017 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
61092050 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
36367555 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
3211028 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
249193 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
7261588 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
8632893 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
2498417 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
14984000 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
86394383 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
217241 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
1114332 USD
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
86394383 USD
CY2017Q4 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1
BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
1055333 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
119000 USD
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
517261 USD
CY2018Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
600000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
674000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
119000 USD
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
119000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
119000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
119000 USD
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3331995 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3154590 shares
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104010432 USD
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
63574383 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10863122 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3626541 USD
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
118600000 USD
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
226500000 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3648541 shares
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
79000 USD
CY2018Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
200000 USD
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
37112775 USD
CY2018 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99749199 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106891503 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103189328 USD
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
85500745 USD
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
50731008 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54925712 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118500095 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107636973 USD
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34578040 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35908057 shares
CY2017Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
508133 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
34578 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
35908 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9024235 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8891966 USD
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
56100000 USD
CY2017 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
5376215 USD
CY2018 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
273453287 USD
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
361132111 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
467804899 USD
CY2018Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
1002468 USD
CY2019 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
1400000 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
19219251 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
21058703 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
9034736 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
24556136 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
30704875 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
14959669 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5336885 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9646172 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5924933 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5952866 USD
CY2018Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
9100000 USD
CY2019Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
8900000 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-18718113 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-5954666 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3508348 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-20669351 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8345235 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6793037 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
16220518 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
10077948 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
19615935 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
18269448 USD
CY2017 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-20675807 USD
CY2018 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-8345235 USD
CY2019 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-6800919 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1951238 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2390569 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3284689 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6414256 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13849685 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1403446 USD
CY2018Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
1886010 USD
CY2019Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
1110659 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
238633 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
277682 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1660664 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1293164 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1124917 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
544028 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
168413 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
188075 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3395417 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3400000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8200000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8191500 USD
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
19615935 USD
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
18269448 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
24084892 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
29195045 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
3544315 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
792781 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1286087 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
927011 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 USD
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 USD
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000 USD
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19075353 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19303179 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18753270 USD
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
0 USD
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
271279 USD
CY2017Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 USD
CY2018Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 USD
CY2019Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
271279 USD
CY2018Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
17500000 USD
CY2019Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1488313 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
225000 USD
CY2018Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
13000000 USD
CY2019Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.01
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.029
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.137
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.194
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.007
CY2019 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.027
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.018
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.015
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.014
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.081
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.078
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.271
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.316
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4996906 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3237565 USD
CY2019 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
10200000 USD
CY2018Q4 us-gaap Equity Method Investments
EquityMethodInvestments
34876980 USD
CY2019Q4 us-gaap Equity Method Investments
EquityMethodInvestments
28427455 USD
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
60999 USD
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
70118 USD
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
17179 USD
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
517260 USD
CY2019 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
17179 USD
CY2018Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
101741 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
101741 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
415519 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
554935 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
118920 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
79255 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
118920 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
118920 USD
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
118920 USD
CY2019Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
37675 USD
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
101741 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
500000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
300000 USD
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
101741 USD
CY2019Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0300
CY2019Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M1D
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
57600117 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
73517151 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
39099000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
16026000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
9830000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
10842000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
12673000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
14542000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
103012000 USD
CY2018 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
0 USD
CY2019 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
34047000 USD
CY2019Q4 us-gaap Fresh Start Adjustment Increase Decrease Deferred Income Tax Liabilities Noncurrent
FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent
3200000 USD
CY2017 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-44886 USD
CY2018 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2019 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2017 us-gaap Gain Loss On Investments
GainLossOnInvestments
13697018 USD
CY2018 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
CY2019 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
CY2017 us-gaap Gain Loss On Sale Of Notes Receivable
GainLossOnSaleOfNotesReceivable
921938 USD
CY2018 us-gaap Gain Loss On Sale Of Notes Receivable
GainLossOnSaleOfNotesReceivable
0 USD
CY2019 us-gaap Gain Loss On Sale Of Notes Receivable
GainLossOnSaleOfNotesReceivable
0 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-41784 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26249532 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43353787 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41482375 USD
CY2017Q4 us-gaap Goodwill
Goodwill
189847202 USD
CY2018Q4 us-gaap Goodwill
Goodwill
185805880 USD
CY2019Q4 us-gaap Goodwill
Goodwill
238505204 USD
CY2017Q4 us-gaap Goodwill
Goodwill
86197395 USD
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
52699324 USD
CY2017 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
2400000 USD
CY2017 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
2431791 USD
CY2018 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
3798866 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8166632 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
263191 USD
CY2019 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1994000 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3798866 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3800000 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3800000 USD
CY2018 us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
-242456 USD
CY2018 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
-200000 USD
CY2018 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
700000 USD
CY2018 us-gaap Goodwill Subsequent Recognition Of Deferred Tax Asset
GoodwillSubsequentRecognitionOfDeferredTaxAsset
200000 USD
CY2018 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
209002961 USD
CY2019 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
274670676 USD
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2018 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2019 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1994000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
49711113 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
82627131 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25839949 USD
CY2017 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1112541 USD
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-8125285 USD
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-6900859 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3886785 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22359640 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
9700000 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
24362223 USD
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
23642662 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
20200000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3687022 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22669230 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4883243 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4108970 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10713803 USD
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
388138 USD
CY2018 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
8423366 USD
CY2019 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7092994 USD
CY2017 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-6593783 USD
CY2018 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
28363108 USD
CY2019 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
1435306 USD
CY2017 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
0 USD
CY2018 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
0 USD
CY2019 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
488483 USD
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
220925 USD
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2446 USD
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
572213 USD
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
15079346 USD
CY2017Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
144476000 USD
CY2018Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
144476000 USD
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
176529000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
86875883 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
103011849 USD
CY2017 us-gaap Interest Expense
InterestExpense
79689 USD
CY2018 us-gaap Interest Expense
InterestExpense
560515 USD
CY2019 us-gaap Interest Expense
InterestExpense
4733256 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
51043 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
462336 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4257536 USD
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
1015204 USD
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1258638 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2023873 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2400000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4300000 USD
CY2019 us-gaap Lease Cost
LeaseCost
5141294 USD
CY2019Q4 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P10Y
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17570789 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4783381 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3781174 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1788047 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2130226 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2376159 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2711802 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3207506 USD
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P10Y
CY2018Q4 us-gaap Liabilities
Liabilities
106337868 USD
CY2019Q4 us-gaap Liabilities
Liabilities
367653613 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512999049 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
728713347 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
72019647 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
105423915 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
34318221 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
262229698 USD
CY2019Q4 us-gaap Line Of Credit
LineOfCredit
247625000 USD
CY2019Q4 us-gaap Line Of Credit
LineOfCredit
247625000 USD
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
9500000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
232172134 USD
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9500000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9500000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
197750000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
15437500 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
14250000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10687500 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
232172134 USD
CY2018Q2 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
5000000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25182818 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180630636 USD
CY2018 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
167537480 USD
CY2019 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
218564072 USD
CY2018 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
36549348 USD
CY2019 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
33396932 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1100000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1127102 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
116538673 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
116500000 USD
CY2018Q4 us-gaap Minority Interest
MinorityInterest
998320 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
786199 USD
CY2017 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
19697923 USD
CY2018 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1975010 USD
CY2019 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1988646 USD
CY2018 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
200 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14975549 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11176343 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163330712 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26716009 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
51833923 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
25496039 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13673383 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
25801842 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
10835002 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
14116545 USD
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
20022486 USD
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
49432489 USD
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3556772 USD
CY2017 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
61092050 USD
CY2018 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0 USD
CY2019 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14565146 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5805031 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6580039 USD
CY2018Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2019Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
6425000 USD
CY2018Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
0 USD
CY2019Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
16500000 USD
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2019 us-gaap Number Of Reporting Units
NumberOfReportingUnits
3 unit
CY2017 us-gaap Operating Expenses
OperatingExpenses
321209963 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
431475590 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
528198109 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
35145967 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
88432162 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
32419988 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
5437078 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
14363283 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8900000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2990686 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11372597 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
5254079 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14247727 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9000000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0611
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y5M22D
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7117000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2848000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
489000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
487000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
783000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2267000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
243000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1205962 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1680689 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
168102 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1622131 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3030203 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1003133 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
16885448 USD
CY2017 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0 USD
CY2018 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0 USD
CY2019 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
5771444 USD
CY2017 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
-228287 USD
CY2018 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
0 USD
CY2019 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
0 USD
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3175836 USD
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5047643 USD
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7569685 USD
CY2017 us-gaap Payments Of Dividends
PaymentsOfDividends
10447923 USD
CY2018 us-gaap Payments Of Dividends
PaymentsOfDividends
17758808 USD
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
61717367 USD
CY2017 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2018 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2019 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
49402514 USD
CY2017 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 USD
CY2018 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
16706152 USD
CY2019 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
3108000 USD
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5283 USD
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9013 USD
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
115402452 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2084770 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1170064 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1041670 USD
CY2017 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
10000000 USD
CY2018 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
7500000 USD
CY2019 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
11425000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7385098 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10315093 USD
CY2017 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1240000 USD
CY2018 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
607411 USD
CY2019 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
240000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2160736 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
200000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
754998 USD
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000 USD
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
8000000 USD
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
250000000 USD
CY2017 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 USD
CY2018 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 USD
CY2019 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
39600000 USD
CY2017 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-9000000 USD
CY2018 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2019 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2017 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
0 USD
CY2018 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
27300 USD
CY2019 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
27500 USD
CY2017 us-gaap Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
200000 USD
CY2018 us-gaap Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
0 USD
CY2019 us-gaap Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
0 USD
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
164797 USD
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3996677 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3123709 USD
CY2017 us-gaap Profit Loss
ProfitLoss
45824328 USD
CY2018 us-gaap Profit Loss
ProfitLoss
60267491 USD
CY2019 us-gaap Profit Loss
ProfitLoss
17673317 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26722048 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12721082 USD
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3887647 USD
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1363363 USD
CY2018 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
65283000 USD
CY2019 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
47300000 USD
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
102348 USD
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
98735 USD
CY2019 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
101741 USD
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1933588 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
631561 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
939715 USD
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2375000 USD
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
100000 USD
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
75000 USD
CY2017Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
18005661 USD
CY2018Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
0 USD
CY2019Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
75000 USD
CY2017Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
745235 USD
CY2018Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
745470 USD
CY2019Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
746104 USD
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
745470 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
746104 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
17788203 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
31904748 USD
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
356355930 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
519907752 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
560618097 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16727589 USD
CY2018Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
800000 USD
CY2017Q4 us-gaap Share Based Compensation
ShareBasedCompensation
800000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2743116 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1441089 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1546861 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
16.80
CY2018Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
40257 USD
CY2019Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
0 USD
CY2018Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
37593 shares
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
600000 shares
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
488464 shares
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
241214 shares
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5376215 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2059533 USD
CY2017 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1652286 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
180545832 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
191548949 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
87587720 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
164183426 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
181544152 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
192335148 USD
CY2019 us-gaap Sublease Income
SubleaseIncome
414704 USD
CY2018Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
225117029 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
168724586 USD
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1850603 shares
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
17458810 shares
CY2018 us-gaap Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
-432113 USD
CY2019 us-gaap Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
7286385 USD
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
86005 USD
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-25005 USD
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
9119 USD
CY2019 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.50
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28661735 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37914886 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36403279 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25525786 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32893940 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34708429 shares
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the &#8220;Merger Agreement&#8221;) with Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, (&#8220;Merger Subsidiary&#8221;), Network Medical Management, Inc. (&#8220;NMM&#8221;), and Kenneth Sim, M.D., in his capacity as the representative of the shareholders of NMM, pursuant to which Merger Subsidiary merged with and into NMM, with NMM as the surviving corporation (the &#8220;Merger&#8221;). The Merger closed and became effective on December 8, 2017 (the &#8220;Closing&#8221;) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and control of the board of directors of ApolloMed. Effective as of the Closing, ApolloMed&#8217;s board of directors approved a change in ApolloMed&#8217;s fiscal year end from March 31 to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;"> to correspond with NMM&#8217;s fiscal year end prior to the Merger.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and to patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organization (&#8220;HMO&#8221;) plans, with a portion of the Company&#8217;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (&#8220;AMM&#8221;), APA ACO, Inc. (&#8220;APAACO&#8221;) and Apollo Care Connect, Inc. (&#8220;Apollo Care Connect&#8221;), and their consolidated entities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NMM was formed in 1994 as a management service organization (&#8220;MSO&#8221;) for the purposes of providing management services to medical companies and independent practice associations (&#8220;IPAs&#8221;). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California (&#8220;APC&#8221;) was incorporated on August&#160;17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various HMOs or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July&#160;1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of </font><font style="font-family:inherit;font-size:10pt;">30 years</font><font style="font-family:inherit;font-size:10pt;">. In accordance with relevant accounting guidance, APC is determined to be a VIE as NMM is the primary beneficiary with the ability to direct the activities that most significantly affect APC&#8217;s economic performance through its majority representation of the APC Joint Planning Board. Accordingly, APC is consolidated by NMM.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) was formed on May 7, 2019 as a designated shareholder&#160;professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover its losses. AP-AMH's sole function and only activity is to act as the nominee shareholder for ApolloMed's investments in APC. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this variable interest entity (&#8220;VIE&#8221;). </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">September&#160;11, 2019</font><font style="font-family:inherit;font-size:10pt;">, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company loaned AP-AMH </font><font style="font-family:inherit;font-size:10pt;">$545.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year secured loan agreement. The loan bears interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH's assets, including the shares of APC Series A Preferred Stock to be purchased by AP-AMH. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum simple interest.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AP-AMH purchased </font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of APC Series A Preferred Stock for aggregate consideration of </font><font style="font-family:inherit;font-size:10pt;">$545.0 million</font><font style="font-family:inherit;font-size:10pt;"> in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the "Certificate of Determination"), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC's net income from Healthcare Services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC's affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination). During the year ended December 31, 2019, APC distributed </font><font style="font-family:inherit;font-size:10pt;">$8.9 million</font><font style="font-family:inherit;font-size:10pt;"> to ApolloMed as preferred returns.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APC purchased </font><font style="font-family:inherit;font-size:10pt;">15,015,015</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock for total consideration of </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in private placement. In connection therewith, the Company granted APC certain registration rights with respect to the Company's common stock that APC purchased, and APC agreed that APC votes in excess of </font><font style="font-family:inherit;font-size:10pt;">9.99%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's then outstanding shares will be voted by proxy given to the Company's management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before the Company's stockholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company licensed to AP-AMH the right to use certain tradenames for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of a result of the transaction, APC's ownership in ApolloMed increased to </font><font style="font-family:inherit;font-size:10pt;">32.50%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> from </font><font style="font-family:inherit;font-size:10pt;">4.82%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed on March&#160;25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of December 31, 2019 APC's ownership percentage in CDSC&#8217;s capital stock was </font><font style="font-family:inherit;font-size:10pt;">45.01%</font><font style="font-family:inherit;font-size:10pt;">. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APC-LSMA Designated Shareholder Medical Corporation ("APC-LSMA") was formed on October 15, 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation ("Accountable Health Care"), and AMG, a Professional Medical Corporation ("AMG").</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpha Care, an IPA, was acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> by APC-LSMA on May 31, 2019 for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$45.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, has been operating in California since 1993 and is a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to over </font><font style="font-family:inherit;font-size:10pt;">174,000</font><font style="font-family:inherit;font-size:10pt;"> enrollees, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and focuses on Medi-Cal/Medicaid, Commercial, Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California (see Note 3).</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accountable Health Care is a California based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. Accountable Health Care currently has a network of over </font><font style="font-family:inherit;font-size:10pt;">400</font><font style="font-family:inherit;font-size:10pt;"> primary care physicians and </font><font style="font-family:inherit;font-size:10pt;">700</font><font style="font-family:inherit;font-size:10pt;"> specialty care physicians, and </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> community and regional hospital medical centers that provide quality health care services to more than </font><font style="font-family:inherit;font-size:10pt;">84,000</font><font style="font-family:inherit;font-size:10pt;"> members of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock they did not already own (comprising </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">) for </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (see Note 3 and Note 6).</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMG is a network of family practice clinics operating in </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its networks of doctors and nurse practitioners. On September 10, 2019, APC-LSMA acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate issued and outstanding shares of capital stock of AMG for </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of APC common stock (see Note 3).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> owned subsidiary of APC, was formed on June&#160;4, 2014, for the purpose of holding the investment in Universal Care, Inc. (&#8220;UCI&#8221;). </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAACO, a wholly-owned subsidiary of ApolloMed, has participated in the next generation accountable care organization (&#8220;NGACO") model of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) since January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM previously operated three accountable care organizations (&#8220;ACOs&#8221;) that participated in the Medicare Shared Savings Program (&#8220;MSSP&#8221;), the goal of which was to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an &#8220;all or nothing&#8221; basis.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, consisting of ApolloMed Hospitalists (&#8220;AMH&#8221;), a hospitalist company and Southern California Heart Centers (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</font></div></div>
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no material effect on net income, cash flows or total assets. </font></div></div>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;The more significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including historical medical loss ratios (&#8220;MLR&#8221;), and incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk revenue and receivables (including constraints and completion factors), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-20-003626-index-headers.html Edgar Link pending
0001628280-20-003626-index.html Edgar Link pending
0001628280-20-003626.txt Edgar Link pending
0001628280-20-003626-xbrl.zip Edgar Link pending
ameh-20191231.xml Edgar Link completed
ameh-20191231.xsd Edgar Link pending
ameh-20191231x10k.htm Edgar Link pending
ameh-20191231xexx141.htm Edgar Link pending
ameh-20191231xexx211.htm Edgar Link pending
ameh-20191231xexx231.htm Edgar Link pending
ameh-20191231xexx311.htm Edgar Link pending
ameh-20191231xexx312.htm Edgar Link pending
ameh-20191231xexx313.htm Edgar Link pending
ameh-20191231xexx32.htm Edgar Link pending
ameh-20191231xexx410.htm Edgar Link pending
ameh-20191231_cal.xml Edgar Link unprocessable
ameh-20191231_def.xml Edgar Link unprocessable
ameh-20191231_lab.xml Edgar Link unprocessable
ameh-20191231_pre.xml Edgar Link unprocessable
chart-42be7e02b39bf9c3f11.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending